The FDA handed down a second complete response letter to Zealand Pharma for its glucagon receptor agonist in an ultra-rare ...

Clearside Biomedical reported positive results from a Phase 2b trial of its tyrosine kinase inhibitor in patients with wet ...

If all goes according to plan, insitro could finally start testing its first drug in clinical trials in 2026, eight years ...

London-based startup Basecamp Research has closed a $60 million Series B round that will help expand its genomic database and ...

Concentra Biosciences, a shell company from Tang Capital, wants to buy another biotech that has found itself in a bind. Kevin ...

Purespring Therapeutics has reeled in £80 million ($105 million) to test two gene therapies in humans. The Sofinnova Partners ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 ...

Data submitted to the FDA by Stealth BioTherapeutics for its ultra-rare disease drug likely aren’t sufficient for an approval ...

City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of ...

A trade group for large compounding pharmacies sued the FDA over its move to take Eli Lilly’s blockbuster GLP-1 drug off its ...

A protein called alpha-synuclein that accumulates and ravages the brains of some people with Parkinson’s disease is the ...